JP2009517473A5 - - Google Patents

Download PDF

Info

Publication number
JP2009517473A5
JP2009517473A5 JP2008543378A JP2008543378A JP2009517473A5 JP 2009517473 A5 JP2009517473 A5 JP 2009517473A5 JP 2008543378 A JP2008543378 A JP 2008543378A JP 2008543378 A JP2008543378 A JP 2008543378A JP 2009517473 A5 JP2009517473 A5 JP 2009517473A5
Authority
JP
Japan
Prior art keywords
bcaa
protein
individual
precursor
increase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008543378A
Other languages
English (en)
Japanese (ja)
Other versions
JP5260303B2 (ja
JP2009517473A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/045497 external-priority patent/WO2007064618A1/en
Publication of JP2009517473A publication Critical patent/JP2009517473A/ja
Publication of JP2009517473A5 publication Critical patent/JP2009517473A5/ja
Application granted granted Critical
Publication of JP5260303B2 publication Critical patent/JP5260303B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008543378A 2005-11-30 2006-11-28 筋肉損失の治療のための方法 Expired - Fee Related JP5260303B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74109205P 2005-11-30 2005-11-30
US60/741,092 2005-11-30
US78094106P 2006-03-09 2006-03-09
US60/780,941 2006-03-09
PCT/US2006/045497 WO2007064618A1 (en) 2005-11-30 2006-11-28 Methods for the treatment of muscle loss

Publications (3)

Publication Number Publication Date
JP2009517473A JP2009517473A (ja) 2009-04-30
JP2009517473A5 true JP2009517473A5 (enExample) 2010-01-28
JP5260303B2 JP5260303B2 (ja) 2013-08-14

Family

ID=37806127

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008543378A Expired - Fee Related JP5260303B2 (ja) 2005-11-30 2006-11-28 筋肉損失の治療のための方法

Country Status (17)

Country Link
US (1) US8329646B2 (enExample)
EP (1) EP1957061B1 (enExample)
JP (1) JP5260303B2 (enExample)
CN (1) CN101316582A (enExample)
AT (1) ATE508745T1 (enExample)
AU (1) AU2006320670B8 (enExample)
BR (1) BRPI0619179A2 (enExample)
CA (1) CA2631647A1 (enExample)
DK (1) DK1957061T3 (enExample)
ES (1) ES2363442T3 (enExample)
IL (1) IL191374A0 (enExample)
MY (1) MY147489A (enExample)
PT (1) PT1957061E (enExample)
RU (1) RU2414897C2 (enExample)
SG (1) SG163600A1 (enExample)
WO (1) WO2007064618A1 (enExample)
ZA (1) ZA200805657B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101282657A (zh) * 2005-10-28 2008-10-08 雀巢技术公司 支链氨基酸的使用方法
DE102007016715A1 (de) * 2007-04-04 2008-10-09 Evonik Degussa Gmbh Nahrungsergänzungsmittel enthaltend alpha-Ketosäuren
CA2706656A1 (en) * 2007-11-26 2009-06-04 Nestec S.A. Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition
MX2010008726A (es) * 2008-02-07 2010-08-31 Nestec Sa Composiciones y metodos para influir en la recuperacion a partir de actividad fisica intensa.
EP2274002B1 (en) * 2008-03-26 2014-12-03 Glanbia Nutritionals (Ireland) Limited Leucine-rich peptide compositions and methods for isolation
US20130236447A1 (en) * 2008-12-23 2013-09-12 Carmel-Haifa University Economic Corp., Ltd. Cognitive function
BR112012019902A2 (pt) 2010-02-10 2019-09-24 Novartis Ag "método e compostos para o crescimento muscular"
KR20140007926A (ko) * 2011-02-25 2014-01-20 메르크 파텐트 게엠베하 관절 및/또는 자세의 안정성을 증가시키기 위한 조성물
RU2454227C1 (ru) * 2011-04-05 2012-06-27 Федеральное государственное учреждение "Российский научный центр "Восстановительная травматология и ортопедия" имени академика Г.А. Илизарова" Министерства здравоохранения и социального развития Российской Федерации Композиция для восстановления скелетных мышц и кости при скелетной травме
PH12014500198A1 (en) 2011-07-15 2017-02-10 Nusirt Sciences Inc Compositions and methods for modulating metabolic pathways
EP2813224A4 (en) * 2012-02-06 2015-06-24 Ajinomoto Kk PROPHYLACTIC OR THERAPEUTIC AGENTS AGAINST IDIOPATHIC INFLAMMABLE MUSCLE DISEASES
WO2013148325A1 (en) 2012-03-26 2013-10-03 Pronutria, Inc. Nutritive fragments, proteins and methods
WO2013148328A1 (en) 2012-03-26 2013-10-03 Pronutria, Inc. Nutritive proteins and methods
JP2015513904A (ja) 2012-03-26 2015-05-18 プロニュートリア・インコーポレイテッドＰｒｏｎｕｔｒｉａ， Ｉｎｃ． 栄養断片、タンパク質、および方法
RU2014143029A (ru) 2012-03-26 2016-05-20 Проньютриа, Инк. Заряженные питательные белки и способы их применения
JP5477413B2 (ja) * 2012-04-24 2014-04-23 味の素株式会社 分岐鎖アミノ酸の心不全適応
JP6469015B2 (ja) 2012-11-13 2019-02-13 ニューサート サイエンシーズ， インコーポレイテッド エネルギー代謝を増大させるための組成物および方法
RU2517576C1 (ru) * 2013-03-06 2014-05-27 Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации-Институт медико-биологических проблем Российской академии наук (ГНЦ РФ-ИМБП РАН) Средство для профилактики и снижения деструкции белков скелетных мышц при их атрофии, вызванной гипокинезией и/или гравитационной разгрузкой
ES2844199T3 (es) 2013-04-16 2021-07-21 Childrens Hospital Philadelphia Composiciones y métodos para el tratamiento de lesiones cerebrales
MX2015015178A (es) * 2013-05-01 2016-02-26 Abbott Lab Metodos para potenciar la regeneracion de musculos envejecidos.
CN103416760B (zh) * 2013-08-28 2014-09-10 山东卫康生物医药科技有限公司 治疗和预防肌肉衰减综合症的五谷杂粮全营养配方食品
EP3048904A2 (en) 2013-09-25 2016-08-03 Pronutria Biosciences, Inc. Compositions and formulations for treatment of gastrointestinal tract malabsorption diseases and inflammatory conditions and methods of production and use thereof
KR101668074B1 (ko) * 2015-02-12 2016-10-21 전북대학교산학협력단 Ｐｋｒ 저해제를 유효성분으로 포함하는 기관지 천식의 예방 또는 치료용 조성물
CN105747214A (zh) * 2016-02-26 2016-07-13 四川安益生物科技有限公司 一种支链氨基酸组合物
CN110234334B (zh) * 2016-12-05 2024-02-06 大塚制药株式会社 肌肉萎缩抑制组合物
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US10682325B2 (en) 2017-08-14 2020-06-16 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
CN107440126A (zh) * 2017-09-08 2017-12-08 天津活力达生物科技有限公司 一种缓解运动疲劳的蛋白粉及其制备方法
WO2019204633A1 (en) * 2018-04-18 2019-10-24 Worlds Greatest Ingredients, LP Compositions and methods of use thereof to promote muscle growth and function
RU2686086C1 (ru) * 2018-05-17 2019-04-24 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ коррекции пресаркопении или саркопении у пациента с адекватным потреблением основных нутриентов, получающего лечение программным гемодиализом
JP2021527670A (ja) 2018-06-20 2021-10-14 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． 筋肉中の脂肪浸潤の治療のための組成物及び方法
CA3143450A1 (en) * 2019-06-20 2020-12-24 Societe Des Produits Nestle S.A. Compositions and methods to potentiate musculoskeletal effect of one or more anabolic amino acids
IT201900010437A1 (it) * 2019-06-28 2020-12-28 Dompe Farm Spa Composizione per il trattamento del deperimento muscolare

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4491589A (en) * 1982-05-17 1985-01-01 The Trustees Of Columbia University In The City Of New York Amino acid solutions for parenteral nutrition and methods of formulation and use
US4677121A (en) * 1985-01-22 1987-06-30 The Johns Hopkins University Method of inhibiting muscle protein degradation
US4780475A (en) * 1986-02-03 1988-10-25 Cerra Frank B Preparation for the prevention of catabolism
US5087472A (en) * 1990-01-30 1992-02-11 Iowa State University Research Foundation, Inc. Feed compositions for domestics animals containing hydroxymethylbutyrate
JPH03264525A (ja) * 1990-03-14 1991-11-25 Otsuka Pharmaceut Factory Inc アミノ酸輸液
US6608109B2 (en) * 1991-11-20 2003-08-19 Allen Ann De Wees Composition comprising L-arginine as a muscle growth stimulant and use thereof
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
US5716926A (en) * 1996-07-26 1998-02-10 Paxton K. Beale Composition of pyruvate and protein and method for increasing protein concentration in a mammal
DE19757250A1 (de) * 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
US5817695A (en) * 1997-12-24 1998-10-06 Pellico; Michael A. Nutritional product with high fat, low carbohydrate and amino acid imbalance
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
IL141724A0 (en) * 1998-08-28 2002-03-10 Scios Inc INHIBITORS OF P38-α KINASE
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6051236A (en) * 1998-11-12 2000-04-18 Pacifichealth Laboratories, Inc. Composition for optimizing muscle performance during exercise
CA2399500A1 (en) * 2000-02-01 2001-08-09 Muscletech Research And Development Inc. Alpha lipoic acid based food supplement for increasing lean muscle mass and strength
WO2002062792A1 (en) * 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients
FR2833012B1 (fr) * 2001-12-04 2004-01-30 Centre Nat Rech Scient Peptides agonistes de l'hormone de croissance et leurs applications
US7744930B2 (en) * 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
US8703209B2 (en) * 2003-06-17 2014-04-22 Edward Larry McCleary Composition and method for modulating hydrogen ion physiology
US7820702B2 (en) * 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
CA2577987A1 (en) 2004-08-25 2006-03-02 Santhera Pharmaceuticals (Schweiz) Ag Alpha-keto carbonyl calpain inhibitors
CN101282657A (zh) * 2005-10-28 2008-10-08 雀巢技术公司 支链氨基酸的使用方法
US7790688B2 (en) * 2008-01-11 2010-09-07 Healthspan Solutions, Llc Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly

Similar Documents

Publication Publication Date Title
JP2009517473A5 (enExample)
WO2007064618A8 (en) Methods for the treatment of muscle loss
JP2007527914A5 (enExample)
SI2012763T1 (sl) Farmacevtska kombinacija, ki obsega 3-(3-dimetilamino-1-etil-2-metil- propil)-fenol in NSAID
JP2005518433A5 (enExample)
FI3782612T3 (fi) Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi
SI2205244T1 (sl) Postopki dajanja N-(5-terc.-butil-izoksazol-3-il)-N'-(4-(7-(2-morfolin- 4-il-etoksi-)imidazo-2,1-b)-(1,3)-benzotiazol-2-il)-fenil)sečnine za zdravljenje proliferativne bolezni
EA201100958A1 (ru) Фармацевтическая пероральная дозированная лекарственная форма на основе ингибиторов dpp iv
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
JP2011511805A5 (enExample)
BRPI0710682B8 (pt) combinação farmacêutica compreendendo 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol e paracetamol
DK2043637T3 (da) Fremgangsmåder og medikamenter til administrering af ibuprofen
JP2013510169A5 (enExample)
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
NO20082636L (no) Anvendelse av DHA og ARA for fremstilling av en sammensetning for forebygging eller behandling av fedme
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2013062442A3 (ru) Композиция для лечения рассеянного склероза (варианты)
JP2009505991A5 (enExample)
EA200801890A1 (ru) Средство для лечения шума в ушах
WO2010098625A2 (ko) 약제학적 제제
JP2009523124A5 (enExample)
MX2009006670A (es) Composicion farmaceutica que usa el aliskiren y el avosentan.
IS7899A (is) Samverkandi samsetning sem felur í sér róflúmílast og (R.R)-formóteról
EA200701010A1 (ru) Препарат гепирона с высокой дозировкой и длительным высвобождением
JP2007230991A5 (enExample)